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Abstract
Purpose: The purpose of this article is to assemble, review, and provide a synopsis of the historical
and current literature regarding optimal sequencing of radiation (RT) and immunotherapy
combination treatments.
Materials and methods: A review of the literature was performed using PubMed with the query
“radiation” and “Immunotherapy”, “PD1”, “PDL1”, “CTLA4”, “OX40”, “checkpoint”, “vaccine”,
“macrophage”, “STING”, and “TGFbeta”. Studies that included sequencing of therapy were
evaluated and the studies were included at the authors discretion.
Results: A paucity of primary literature exists examining the best order of radiation and
immunotherapy, most of which was performed in the pre-clinical setting. The observations are that
optimal sequencing of various radiation plus immune therapy combinations is dependent on the
mechanism(s) of activation by the combination treatment. Immunosuppressive molecules tend to
be better inhibited prior to RT while engagement of costimulatory genes is better activated
concomitantly with RT.
Conclusions: These data should compel more basic research into both the direct investigation of
sequencing efﬁcacy and studies on the mechanisms of immune mediated cell death potentiated by
radio-therapy.
Ó 2018 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).

Purpose
The advent of immune therapies approved by the U.S.
Food and Drug Administration for patients with late-stage
cancer, which consist primarily of monoclonal antibodies
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* Corresponding author. Earle A. Chile Research Institute, Portland,
OR 97213.
E-mail address: kristina.young@providence.org (K.H. Young).

(mAbs) that neutralize the inhibitory actions of T-cell
checkpoint molecules, has stimulated a wave of research
into novel immune-oncology (IO) combination treatment
strategies. The central hypothesis of these strategies
hinges on the idea that cell-mediated cytotoxicity can be
harnessed and exploited to eradicate existing tumors as
well as surveil undetectable malignancies. The evidence
that necessitates this research is clear, but despite
remarkable responses in melanoma,1 responses to
treatment are much more modest in other tumor types
where the majority of patients do not respond. Among

https://doi.org/10.1016/j.adro.2018.07.005
2452-1094/Ó 2018 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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patients who exhibit an objective response, many become
therapeutic resistant while on immune checkpoint
blockade (ICB) treatment. As more immunotherapeutic
options become available, determining when to use them
and how to combine them with standard-of-care cytotoxic
therapy is critical.
Radiation is a common antineoplastic treatment
modality that is primarily related to its efﬁcacy as a focal
cytotoxic agent. Additional beneﬁts of radiation are its
ability to expose tumor antigens, create a focal
inﬂammatory response, enhance major histocompatibility
complex upregulation, induce maturation of antigenpresenting cells, lead to danger-associated molecule
pattern (DAMP)/pathogen-associated molecular pattern
expression, and sensitize tumor cells to immune-mediated
killing to create a potent in situ vaccine.2e4 Primarily
because of this, combination radiation and immunotherapy
can enhance efﬁcacy over either modality alone. Herein,
we will discuss the data for the most effective combination
of radiation and various immunotherapies to potentiate the
vaccination effect (Table 1). Speciﬁcally, we will focus on
the sequencing of treatments to maximize tumor killing
both locally and in metastatic tissues.

Methods and Materials
A review of the literature was performed using PubMed
with the query “radiation” and “Immunotherapy”, “PD1”,
“PDL1”, “CTLA4”, “OX40”, “checkpoint”, “vaccine”,
“macrophage”, “STING”, and “TGFbeta”. Studies that
included sequencing of therapy were evaluated and the
studies were included at the authors discretion.

Results
Combination radiation and immunotherapy
rationale
Although initially approved for metastatic melanoma
with objective response rates up to 40%, some cancers
such as pancreatic adenocarcinoma are virtually
unresponsive to ICB monotherapy.1,5,6 A recently
identiﬁed biomarker to predict which patients are
susceptible to ICB efﬁcacy is the categorization of tumors
as those with an already established T-cell inﬂamed
phenotype (ie, hot tumors) and those with a relative
paucity of T-cell inﬁltrates (ie, cold tumors) before ICB
treatment.7,8 The inﬂuence of T-cell inﬁltrate on response
to standard-of-care treatment (excluding immunotherapy)
is the number 1 independent prognosticator of
cancer-speciﬁc survival in colorectal cancer9,10 and has
led to a 6-year global effort to standardize the
immunoscore as deﬁned by the level of cluster of
differentiation (CD)3þ/8þ T-cell inﬁltration.
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These biomarkers are strongly considered to enhance
patient stratiﬁcation and likely will be employed for the
clinical practice of some cancer types, which is a
remarkable example of progress and translation from
research to clinical practice. Additional biomarkers for
response to ICB include the sum total of somatic
mutations acquired in an individual’s tumor, which
portends an enhanced immunogenic state because of the
acquisition of neo-antigens presented by cancer cells that
can stimulate endogenous immunity.7,11 Indeed, a strong
association between ICB-responsive patients with higher
tumor mutational burdens has been demonstrated.12
Curiously, these molecular patterns do not explain the
difference between T-cell rich and poor tumors that are
naturally generated from treatment-naïve melanomas.13 To
convert the phenotype of cold tumors into T-cell rich
microenvironments, conventional cytotoxic therapies using
ionizing radiation have signiﬁcant utility. Radiation
increases tumor-inﬁltrating T cells, both naïve and
antigen-speciﬁc CD8þ T cells.14 Exceedingly rare case
report observations have long ago shown that radiation of
a particular malignant lesion can lead to partial or complete
regression of an unirradiated lesion within the same patient
(abscopal effect).15 This indicates that radiation therapy
(RT) can elicit local and systemic antitumor immunity and
provides an interventional opportunity to increase the
frequency and magnitude of this abscopal response for
complete tumor rejection and immune memory.
Preclinical evidence has revealed that the mechanism
that mediates these abscopal responses is dependent on
CD8þ cytotoxic T lymphocytes. However, differences in
radiation dose, fractionation, and sequence can have
signiﬁcant alterations on leukocyte function,16,17 which
highlights the need to understand immune response
mechanisms to RT-induced cell death and tissue stress
responses.
Immune-system activation is carefully controlled
within tissues and ﬁnely balanced between eliminating
pathogenic insults and repairing damaged tissue while
limiting collateral tissue destruction through the
suppressive actions of various immune regulatory cell
types (eg, Tregs, Bregs, and M2 macrophages, which are
discussed in more detail elsewhere in this issue).18,19
Progressing cancers escape immune recognition and
rejection in large part by co-opting these immune
regulatory cells and wound-repair phenotypes to assist
with angiogenesis, matrix remodeling, and cytotoxic
T-cell inhibition.20 Ionizing radiation can elicit greater
proportions of nearly all these immunoregulatory cell
types attributed to the activation of apoptotic cell death
pathways in these regulatory cells, which favors
resolution of immune function over potentiating
inﬂammation.19 To capitalize on the window of
immune stimulation after radiation, cell-death-associated
immunosuppression must be counteracted to prolong
T-cell activation and residency within tumors. To that
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Druzd, D. et al. Lymphocyte Circadian Clocks Control Lymph
Node Trafﬁcking and Adaptive Immune Responses Article
Lymphocyte Circadian Clocks Control Lymph Node
Trafﬁcking. Immunity 1e13 (2017). https://doi.org/10.1016/j.
immuni.2016.12.011
Messenheimer, D. J. et al. Timing of PD-1 blockade is critical to
effective combination immunotherapy with anti-OX40. Clin.
Cancer Res. 23, 6165e6177 (2017).
Crittenden, M. R. et al. Mertk on tumor macrophages is a
therapeutic target to prevent tumor recurrence following
radiation therapy. Oncotarget 7, (2014).

x

end, performing radiation with therapies that target this
suppression is appealing. Currently, macrophage
inhibitors,21 Treg depletion,22,23 PI3Kg antagonism,24
and indoleamine 2, 3-dioxygenase 1 blockade25,26 are
promising immunoregulatory targets explored in clinical
trials in a variety of indications. Preclinical evidence for
enhanced systemic immune responses after radiation and
immunotherapy when Tregs are depleted has laid the
groundwork to move this research forward to the clinic.27

Altering tumor-inﬁltrating T cells before
radiation
When formulating the correct sequencing of radiation
and immunotherapies, understanding how the pre-existing
immune microenvironment inﬂuences responses to RT is
beneﬁcial. Whole exome sequencing is becoming a
standard laboratory practice for many cancer centers,
primarily to identify molecular targets that can be treated
with small molecule inhibitors of dominant oncogenic
pathways. However, this offers an additional opportunity
to characterize the immunological landscape for research
and therapeutic exploitation, including the identiﬁcation
of tumor antigens and neoantigens, immune inﬁltrate and
polarization, and cytokine proﬁle. For those with cold
tumors with potentially hidden or cryptic immune epitopes, radiation before whole exome sequencingedirected
vaccination might be counterproductive.
Because response to radiation is partially dependent on
CD8þ T cells,28 strategies to increase T-cell inﬁltrate may
improve radiation efﬁcacy (Fig 1). Targeting tumorcellespeciﬁc neoantigens in the forms of personalized
vaccine and antigen-speciﬁc T-cell transfer can mediate
tumor regression in patients with treatment-resistant
tumors.39e41 Preclinical studies that combine radiation
and tumor-antigen vaccines have resulted in enhanced
responses over either modality alone,42 but genetic and
cellular heterogeneity between patients likely precludes a

Clinical
Retrospective

Clinical
Prospective

x

x

one-size-ﬁts-all approach to this particular combination
therapy.
However, the combination of radiation and speciﬁc
tumor-antigen vaccines can lead to the regression of
tumors with disparate antigens because of antigen
cascade.37 Furthermore, T-cell priming to tumor antigens
in implantable mouse models has recently been shown
to occur in direct response to tumor cell injection,
precluding the therapeutic generation of de novo
immunity.43 This provides a unique animal model to
study immune-boosting scenarios to custom antigens, but
is clearly an experimental artifact contrary to the 10-year
average of human carcinogenesis.44
Despite these caveats, the majority of patients with
cancer likely have sufﬁciently primed T cells at the time
of diagnosis, and thus strategies to boost pre-existing
immunity in these patients using local radiation would
likely focus on enhancing cross-presentation and
promoting TH1 type inﬂammation. Clearly, more direct
research on the mechanisms of radiation as an in situ
vaccine is necessary to clarify these outstanding
questions, as discussed in this special issue.

Radiation and immune checkpoint blockade
A robust T-cell inﬁltrate may be rendered ineffective
via upregulation of immune checkpoint molecule
expression. The combination of radiation and checkpoint
blockade aims to enhance T-cell inﬁltrate into the tumor
and prevent T-cell functional suppression. When
evaluating the ideal timing of radiation and antiprogrammed cell death protein 1 (PD-1) therapy,
concurrent treatment was superior to sequential treatment,
which suggests that an upregulation of anti-PD-1/
programmed death-ligand 1 (PD-L1) occurs rapidly
after radiation (Fig 1).31 This timing is consistent
with radiation-increasing interferon that leads to the
upregulation of immune checkpoints.
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Figure 1 Ideal efﬁcacy of immune therapies around radiation. Studies demonstrate regulatory T-cell depletion or inhibition before
radiation have enhanced efﬁcacy.29,30 Nondepleting anticytotoxic T-lymphocyte associated protein 4 and antiprogrammed cell death
protein 1 therapy are effective when delivered concurrently with radiation.29,31e33 Agonist anti-OX40 antibodies are most effective
within 24 hours of delivering radiation. Transforming growth factor beta inhibition before and concurrently with radiation has
demonstrated increased efﬁcacy.34,35 Macrophage repolarization after radiation improves radio-response.36 Vaccination before and after
radiation can lead to antigen spreading and systemic tumor responses, including tumors with disparate antigens.37 Stimulator of
interferon gene agonists delivered concurrently and after radiation demonstrate improved efﬁcacy.38

Furthermore, resistance to ICB alone can develop via
downregulation of antigen presentation machinery,45
which hypofractionated radiation may be able to
salvage.46 Recent data also demonstrate that tumor cures
from radiation and immune checkpoint blockade require
pre-existing immunity, and that treatment does not
generate a sufﬁcient de novo immune response.43
Recently, data from the landmark PACIFIC trial for
patients with stage III locally advanced and unresectable
non-small cell lung cancer revealed that the addition of
consolidation durvalumab (anti-PD-L1 mAb) signiﬁcantly
improved progression-free survival over placebo plus
chemoradiation alone.47 Although not directly assessing
the difference between radiation and immune-therapy
sequencing, there was an important trend of improved
responses for patients who received anti-PD-L1 mAb
closer to the chemoradiation administration. This
potentially indicates that concomitant combination
therapy may be more optimal than signiﬁcantly delaying
immune checkpoint blockade.
Of even greater importance may be the responses of
PD-L1 low/negative patients and nonsmokers to
durvalumab therapy, which suggests a potential
conversion of immunogenic-poor patients to T-cell rich
environments by standard cytotoxic therapies. Other
clinical trial results in breast cancer that combine
chemotherapy with ICB mirror the treatment kinetics
observed here (NCT02513472, clinicaltrials.gov).
Converse to the ideal timing of anti-PD-1 mAb around
radiation, a preclinical study evaluating the timing of
radiation and checkpoint blockade with anticytotoxic
T-lymphocyte associated protein 4 (CTLA4) determined
that the combination was the most effective when given 7

days preceding a single 20-Gy dose of radiation as
opposed to concurrently or after RT (Fig 1).29
Interestingly, this timing did not confer efﬁcacy when
using an agonist anti-OX40 antibody in the same model
where 1 day after RT was the most effective course of
combination treatment (Fig 1). This likely reﬂects the
differing mechanisms of anti-CTLA4 versus anti-OX40
on T-cell biology. CTLA4 is known to raise the
threshold for T-cell priming by blocking co-stimulation
and is constitutively expressed after T-cell priming, but
OX40 is transiently upregulated after antigen exposure
and can serve as a powerful co-stimulatory molecule that
is secondary to others, such as CD28.48,49
In addition, CTLA4 expression is the highest on
regulatory T cells (Tregs), but OX40 expression is
higher on other T-cell subsets, which indicates preferential binding to different cell populations. Furthermore,
certain antibody isotypes are known to enhance
antibody-dependent cell cytotoxicity of target cells and
in this study, Treg depletion by anti-CTLA4 mAb was
hypothesized to be partially responsible for the enhanced
radiation efﬁcacy. This approach has since been
conﬁrmed in independent studies to speciﬁcally deplete
tumor Tregs.27,30 Retrospective clinical reports have
found that the delivery of anti-CTLA4 before radiation
correlated with improved survival.50,51 Consistent with
this observation, 2 phase 1 trials have published their
results combing RT with ipilumimab (Ipi) in patients
with metastatic melanoma. The initial trial delivered
stereotactic body RT followed by 4 cycles of Ipi, and the
second trial delivered Ipi ﬁrst, followed by RT 5 days
later, then continued Ipi for a total of 4 cycles.
Interestingly, stereotactic body RT followed by Ipi
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resulted in an 18% partial response as the best
response52 compared with a 50% complete þ partial
response rate in the trial where Ipi preceded radiation,
which also demonstrated a 27% complete response
rate.53
In addition, the results of a recently completed phase 1
trial that attempted to limit the toxicity of Ipi by directly
injecting tumors with TLR9-agonist SD-101 and Ipi
followed by radiation a day later demonstrated only
1 partial response, with a median time to progression of
3 months (NCT02254772, clinicaltrials.gov). These
results suggest less efﬁcacy that is either related to the
route of administration or the timing of radiation after
injection. Of note, in preclinical models, the sequencing
of anti-CTLA4 concurrently or after radiation still
improved survival relative to radiation alone,
presumably through the effects on the checkpoint
blockade of CD8þ T cells.29
Consistent with these ﬁndings, anti-CTLA4 and
radiation efﬁcacy with concurrent therapy was dependent
on CD8 T cells and correlated with decreased
metastases.32 Patients who demonstrated a response to RT
and Ipi had higher levels of central memory CD8þ T cells
and enhanced cytokine production by CD8þ T cells
compared with patients who did not respond.53

Radiation and stimulator of interferon gene
agonists
The stimulator of interferon genes (STING) is the
primary mediator of type 1 interferon upregulation upon
radiation treatment and performs this function through the
recognition of cyclic dinucleotides (CDN) that are derived
from cytosolic DNA. Radiation and CDNs have been
combined using concurrent and post-RT dosing of CDN
for enhanced efﬁcacy, analogous to CDNs as an adjuvant
to the radiation vaccine (Fig 1).38 This timing may be due
to the reported dependency on STING and type 1
interferon upregulation signaling for immune stimulation
by radiation.54e56
Recent work evaluated an additional mechanism by
which combination radiation and anti-CTLA4 enhances
immune-mediated tumor clearance via the STING
pathway.57 Interestingly, the results also report that
dose-dependent upregulation of 3 prime repair
exonuclease 1 (Trex1) expression leads to the degradation
of cytosolic DNA and blunting STING activity. Together,
these data suggest that very high dose radiation may be
poorly immunogenic because of Trex1 degradation of
CDNs. A more in-depth discussion of radiation and DNA
sensing can be found in another review in this special
issue. However, Trex1 expression may explain previous
observations that fractionated doses of radiation better
support CTLA4 combinatorial efﬁcacy.33
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Radiation and cytokines
Radiation may serve not only as an enhancer of
tumor antigen cross-presentation,58 but also as a driver
of polarized cytokine microenvironments. Stressed and
dying cells are abundant sources of danger signals such
as high mobility group box 1, heat shock proteins,
adenosine 50 -triphosphate, reactive oxygen species, and
double stranded DNA.19 Resident phagocytes such as
dendritic cells and macrophages are keen sensors of
these DAMP, primarily to scavenge off of pathogens but
also repair damaged tissue. The default genetic programming of phagocytes after the recognition of
DAMPs is to generate inﬂammation within the corresponding tissue.
However, in response to granulocytic inﬂammation,
macrophages quickly convert to T-cell immunosuppression, tissue remodeling, and the promotion of endothelial
and epithelial cell proliferation. Dendritic cells and
macrophages can be skewed to prolong tissue inﬂammation, antigen presentation, and epithelial cell cytostasis if
they are compelled toward phenotypes more commonly
found in acutely infected or inﬂamed tissues. These
observed phenotypic states are marked by high expression
levels of tumor necrosis factor alpha, interferon
alpha/beta, inducible nitric-oxide synthase, antigen
presentation machinery, costimulatory molecules, and the
T-effector cell chemokines CCL5 and CXCL9/10/
11.59e62
Invariably, in the context of RT, these environments
lead to enhanced tumor rejection accompanied by greater
residency of activated T cells and often incite an abscopal
response that is mediated by the immunologic memory of
tumor-associated antigens. However, radiation often leads
to a wound-healing, immunosuppressive, cytokine
environment that is characterized by a robust M2
macrophage inﬁltrate, transforming growth factor beta
(TGF-b), and adenosine signaling. The optimal window
for intervention targeting these suppressive pathways
might be concurrent or after RT when immunosuppression arises. In that regard, TGF-b1 is a master regulator of
wound repair and immunosuppression by promoting
ﬁbroblast proliferation, blocking naïve T-cell proliferation, and inducing Treg and pericyte differentiation.
Two groups have independently veriﬁed the rationale
of combining TGF-b1 inhibition with RT in mice and
humans.34,35,63,64 Of note, the therapeutic reagents
differed in both studies from small molecule antagonism
of TGF-bR1 signaling and antibody neutralization of
TGF-b1 cytokine, but both preclinical studies delivered
treatment in the same sequence (TGF-b1 blockade
followed by radiation; Fig 1). Because of increased
interferon expression after TGF-b1 inhibition and
radiation leading to the upregulation of PD-L1, the
addition of checkpoint blockade to this regimen has
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proven effective.35,65,66 Contrarily, macrophage depletion
before chemotherapy and radiation in breast cancer mouse
models uniformly demonstrated enhanced cytotoxic
responses,17,67 which suggests tumor tissue type and
perhaps oncogenic signaling may affect sequencing
decisions.

Fractionated radiation and timing of
immunotherapy
The expansion of our knowledge of these systems,
both on the tissue and molecular levels, is requisite to the
precise timing of immunotherapy administered around
traditional cytotoxic approaches. Most of the evidence
presented herein relates to 1 to 5 doses of radiation, as
opposed to the more common clinical scenario of standard
fractionated radiation over weeks to months. How
fractionated radiation inﬂuences the ideal timing of
immunotherapy has been more challenging to address in
preclinical models. One concern with regard to
combination immunotherapy and standard fractionated
radiation is the depletion of T cells in the irradiated ﬁeld
after RT15 because this is expected to attenuate antitumor
immunity. Targeted RT modalities using image-guided
conformal RT greatly minimize the ﬁeld size that is
exposed to radiation; thus, blood volume exposure is
reduced (discussed elsewhere in this issue).
Altering the dose-to-delivery equivalent to increased
bio-equivalent doses in fewer fractions with higher daily
doses (hypofractionation) also results in decreased blood
volume exposure and more immunogenic tumor cell
death. Dose and fractionation inﬂuence on antitumor
immunity is discussed in depth elsewhere in this special
edition as well. There is limited evidence on how best to
sequence immunotherapy with a standard fractionated
radiation, but analyses of immune parameters provide
important information that will impact IO RT trial designs
so that the timing of immune therapies can be coordinated
within the window of greatest opportunity.
For example, an analysis of peripheral blood samples
from 2 independent, nonrandomized, clinical trials
indicated that 30 Gy over 3 fractions in 1 week attenuated
peripheral lymphopenia compared with standard 50.4 Gy
over 28 daily fractions in patients with borderline
resectable and locally advanced pancreatic ductal adenocarcinoma who received neoadjuvant chemoradiation.68
Importantly, both treatment groups qualiﬁed for surgery
in comparable proportions on the basis of a radiographic
assessment, but the duration to normalization of absolute
lymphocyte count was signiﬁcantly lower in the
hypofractionation group, which indicates that bone
marrow and secondary lymphoid organ reserves were
spared from the depletive effects of RT.
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These data suggest that fractionated radiation might
not pair well with T-cell targeting therapies such as
vaccines, checkpoint inhibitors, and agonist costimulatory
antibodies. However, macrophage blockade or antigenpresenting cell adjuvants may have activity and enhance
responses to standard fractionated radiation given their
relative radioresistance compared with lymphocytes. Of
note, T cells are constantly trafﬁcking, and even though
peripheral lymphopenia is observed with fractionated RT,
that may not reﬂect the T-cell population in the tumor
microenvironment, as evidenced by the recent PACIFIC
trial in which peripheral lymphopenia was almost
certainly present in patients when they initiated durvalumab, and yet T-cell targeted therapy was still efﬁcacious.

Conclusions
We outline the current knowledge in the ﬁeld of
radiation and IO combinations but admittedly fail to
sufﬁciently address the gap in knowledge of how to
correctly sequence these combinations. Indeed, precious
few studies have directly compared the efﬁcacy of
ordering pre-, post-, and concurrent radiation treatments
around various IO modalities (Fig 1). The few studies that
have attempted to explore these questions have typically
done so with strongly immunogenic implantable mouse
models or have observed changes in primary tumor
burden, which rarely accounts for cancer-related fatalities.
Conﬂicting data exist in preclinical models.
Differences between study results must be viewed in the
context in which these studies are executed. Not only will
differing mouse strains dictate unique biology, but so can
tissue type, tumor model,69 vivarium microbiome,70 and
even circadian rhythms,71 analogous to unique patient
responses to immunotherapy.
Further consideration must be given to the overstimulation of the immune system with combination
therapy leading to feedback suppression. For example,
one study examined the efﬁcacy of anti-PD-1 checkpoint
blockade pre- and postcostimulation with anti-OX40 in a
middle T-antigen driven luminal B mammary carcinoma
model. Not only did the researchers observe an
enhancement of tumor kill when administering anti-PD-1
antibody after anti-OX40, but also reported a direct
antagonism of efﬁcacy when concurrently giving both
antibodies.72 The most probabilistic explanation is that
when PD-1 signaling is blocked too soon after OX40 costimulation, T-cell exhaustion is accelerated and T-cell
cytotoxicity is rendered less effective. This clearly has
translational relevance to strictly immune-based combinations, but we believe that radiation could mirror the costimulatory effects that are provided by therapeutic
intervention.
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As demonstrated in this review, the mechanism of
immune therapy that is used will directly inﬂuence the
ideal timing in combination with radiation. Further studies
are needed to optimize our efforts. We urge the radiation
oncology community to embrace these research efforts to
rationally design clinical trials based on preclinical data
and with consideration for the immunotherapy mechanism of action.
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